Apixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: an evidence-based review

References

• US Department of Health and Human ServicesThe Surgeon General’s Call to Action to Prevent Deep Vein Thrombosis and Pulmonary EmbolismWashington, DCUS Department of Health and Human Services2008 Available from: http://www.surgeongeneral.gov/library/calls/index.htmlAccessed January 30, 2015
   Google Scholar
• PrandoniPKahnSRPost-thrombotic syndrome: prevalence, prognostication and need for progressBr J Haematol2009145328629519222476
   PubMed Web of Science ®Google Scholar
• KyrlePARosendaalFREichingerSRisk assessment for recurrent venous thrombosisLancet20103762032203921131039
   PubMed Web of Science ®Google Scholar
• DobeshPPEconomic burden of venous thromboembolism in hospitalized patientsPharmacotherapy200929894395319637948
   PubMed Web of Science ®Google Scholar
• KahnSLimWDunnAPrevention of VTE in nonsurgical patients. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelinesChest20121412 Supple195Se226S22315261
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb CompanyCoumadin (Warfarin Sodium) Tablets for Oral Use [prescribing information] Princeton, NJBristol-Myers Squibb Company2011 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/009218s107lbl.pdfAccessed January 30, 2015
   Google Scholar
• O’ReillyRRytandD“Resistance” to warfarin due to unrecognized vitamin K supplementationN Engl J Med19803031601617383081
   PubMed Web of Science ®Google Scholar
• SuttieJWMummah-SchendelLLShahDVLyleBJGregorJLVitamin K deficiency from dietary vitamin K restriction in humansAm J Clin Nutr1988474754803348159
   PubMed Web of Science ®Google Scholar
• BoothSLCharnleyJMSadowskiJADietary vitamin K1 and stability of oral anticoagulation: proposal of a diet with a constant vitamin K1 contentThromb Haemost1997775045099066002
   PubMed Web of Science ®Google Scholar
• WellsPSHolbrookAMCrowtherNRHirshJThe interaction of warfarin with drugs and food: a critical review of the literatureAnn Intern Med19941216766837944078
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim Pharmaceuticals, Inc.Pradaxa (Dabigatran Etexilate Mesylate) Capsules for Oral Use [prescribing information]Ridgefield, CTBoehringer Ingelheim Pharmaceuticals, Inc2015 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022512s024lbl.pdfAccessed January 30, 2015
   Google Scholar
• Janssen Pharmaceuticals Inc. Xarelto (Rivaroxaban) Tablets for Oral Use [prescribing information]Titusville, NJJanssen Pharmaceuticals, Inc2015 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022406s012lbl.pdfAccessed January 30, 2015
   Google Scholar
• Bristol-Myers Squibb CompanyELIQUIS (Apixaban) Tablets for Oral Use [prescribing information]Princeton, NJBristol-Myers Squibb Company2014 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022512s024lbl.pdfAccessed January 30, 2015
   Google Scholar
• Daiichi Sankyo Co.Savaysa (Edoxaban) Tablets for Oral Use [prescribing information]Tokyo, JapanDaiichi Sankyo Co., LTD2015 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdfAccessed January 30, 2015
   Google Scholar
• WongPCCrainEJXinBApixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studiesJ Thromb Haemost2008682082918315548
   PubMed Web of Science ®Google Scholar
• ErikssonBIQuinlanDJWeitzJIComparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in developmentClin Pharmacokinet20094812219071881
   PubMed Web of Science ®Google Scholar
• WeitzJEikelboomJSamamaMNew antithrombotic drugs. Anti-thrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelinesChest2012141(2)(Suppl)e120Se151S22315258
   PubMed Web of Science ®Google Scholar
• Falck-YtterYFrancisCWJohansonNAPrevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelinesChest20121412 supple278Se325S22315265
   PubMed Web of Science ®Google Scholar
• LassenMRRaskobGEGallusAPineoGChenDPortmanRJApixaban or enoxaparin for thromboprophylaxis after knee replacementN Engl J Med2009361659460419657123
   PubMed Web of Science ®Google Scholar
• LassenMRRaskobGEGallusAPineoGChenDHornickPADVANCE-2 InvestigatorsApixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2); a randomized double-blind trialLancet2010375971780781520206776
   PubMed Web of Science ®Google Scholar
• SchulmanSKearonCon behalf of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patientsJ Thromb Haemos20053692694
   PubMed Web of Science ®Google Scholar
• HuangJCaoYLiaoCWuLGaoFApixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomized trialsThromb Haemost2011105224525320941455
   PubMed Web of Science ®Google Scholar
• LassenMRGallusARaskobGEPineoGChenDRamirezLMADVANCE-3 InvestigatorsApixaban versus enoxaparin for thromboprophylaxis after hip replacementN Engl J Med2010363262487249821175312
   PubMed Web of Science ®Google Scholar
• AgnelliGBullerHRCohenAAMPLIFY InvestigatorsOral apixaban for the treatment of acute venous thromboembolismN Engl J Med2013369979980823808982
   PubMed Web of Science ®Google Scholar
• AgnelliGBullerHRCohenAAMPLIFY-EXT InvestigatorsApixaban for extended treatment of venous thromboembolismN Engl J Med2013368869970823216615
   PubMed Web of Science ®Google Scholar
• FrostCWangJNepalSApixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjectsBr J Clin Pharmacol201375247648722759198
   PubMed Web of Science ®Google Scholar
• DouxfilsJChatelainCChatelainBDogneJMMullierFImpact of apixaban on routine and specific coagulation assays: a practical laboratory guideThromb Haemost2013110228329423765180
   PubMed Web of Science ®Google Scholar
• SiéPSamamaCGodierASurgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on perioperative haemostasis and the French Study Group on thrombosis and haemostasisArch Cardiovasc Dis20111041266967622152517
   PubMed Web of Science ®Google Scholar
• SpyropoulosADouketisJHow I treat anticoagulated patients undergoing an elective procedure or surgeryBlood2012120152954296222932800
   PubMed Web of Science ®Google Scholar
• DouketisJSpyropoulosASpencerFPerioperative management of antithrombotic therapy. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelinesChest20121412 Supple326Se3350S22315266
   PubMed Web of Science ®Google Scholar
• NutescuEAOral anticoagulant therapies: balancing the risksAm J Health Syst Pharm20137010 SupplS3S1123640530
   PubMed Web of Science ®Google Scholar
• PathakRPanditAKarmacharyaPMeta-analysis on risk of bleeding with apixaban in patients with renal impairmentAm J Cardiol201511532332725527282
   PubMed Web of Science ®Google Scholar
• GrangerCAlexanderJMcMurrayJApixaban versus warfarin in patients with atrial fibrillationN Engl J Med20113651198199221870978
   PubMed Web of Science ®Google Scholar
• ConnollySEikelboomJJoynerCApixaban in patients with atrial fibrillationN Engl J Med2011354980681721309657
   PubMedGoogle Scholar
• Lopez-JimenezLMonteroMGonzalez-FajardoJAVenous thromboembolism in very elderly patients: findings from a prospective registry (RIETE)Haematologica2006911046105116885044
   PubMed Web of Science ®Google Scholar
• SardarPChatterjeeSChaudhariSLipGNew oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trialsJ Am Geriatr Soc20146285786424786913
   PubMed Web of Science ®Google Scholar
• LevineMNGuCLiebmanHAA randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancerJ Thromb Haemost201210580781422409262
   PubMed Web of Science ®Google Scholar
• HankeyGJIntracranial hemorrhage and novel anticoagulants for atrial fibrillation: what have we learned?Curr Cardiol Rep201416548024643903
   PubMed Web of Science ®Google Scholar
• ToumaLFillonKAtallahRA meta-analysis of randomized controlled trials of the risk of bleeding with apixaban versus vitamin K antagonistsAm J Cardiology2015115533541
   PubMed Web of Science ®Google Scholar
• HylekEHeldCAlexanderJMajor bleeding in patients with atrial fibrillation receiving apixaban or warfarinJ Am Coll Cardiol201463202141214724657685
   PubMed Web of Science ®Google Scholar
• Pfizer LabsHeparin Sodium Injection for Intravenous or Subcutaneous Use [prescribing information]New York, NJPfizer Labs2011 Available from http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201370s000lbl.pdfAccessed January 30, 2015
   Google Scholar
• SiegalDMManaging target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agentsJ Thromb Thrombolysis Epub2015114
   Web of Science ®Google Scholar
• PerlsteinIWangZSongYReversal of apixaban anticoagulation by 4-factor prothrombin complex concentrates in healthy subjects [abstract]Blood201412421345
   Web of Science ®Google Scholar
• LuGDeGuzmanFRHollenbachSJA specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor XaNat Med201319444645123455714
   PubMed Web of Science ®Google Scholar
• CrowtherMGoldALuGANNEXA-A PART 2: A phase 3 randomized, double-blind, placebo-controlled trial demonstrating sustained reversal of apixaban-induced anticoagulation in older subjects by andexanet Alfa (PRT064445), a universal antidote for factor Xa (FXA) inhibitorsJ Thromb Haemost201513Suppl. 2 Abstract LB004
   Google Scholar
• LaulichtBBakhruSLeeCSmall molecule antidote for anticoagulants [abstract]Circulation2012126A11395
   Web of Science ®Google Scholar
• AnsellJEBakhruSHLaulichtBEUse of PER977 to reverse the anticoagulant effect of edoxabanN Engl J Med2014371222141214225371966
   PubMed Web of Science ®Google Scholar
• RevankarNPattersonJKadambiAA Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism preventionPostgrad Med2013125414115323933902
   PubMed Web of Science ®Google Scholar